To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–79
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male and female (without childbearing potential)
Age: ≥18 and ≤79 years of age
Body mass index (BMI): ≥18 and ≤34 kg/m2
Ethnicity: White
Subjects with severe renal impairment on hemodialysis or peritoneal dialysis, and
Healthy subjects
You may not be if
Women of childbearing potential, pregnant or lactating women
Use of medication within the 2 weeks preceding the study which could interfere with the investigational product
Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (HCV Ab), human immune deficiency virus 1 and 2 antibodies (HIV 1/2 Ab)
Exclusion periods from other studies or simultaneous participation in other clinical studies
Clareo Health | To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects
